Needham & Company Reiterates a 'Buy' on Pluristem Therapeutics (PSTI); Comprehensive Program in PAD Planned, Solid Cash Position to Support Operations
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Pluristem Therapeutics (NASDAQ: PSTI), PT $5.
Needham analyst says, "Given the pivotal and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Given the pivotal and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
